Navigation Links
Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
Date:12/14/2010

PRINCETON, N.J., Dec. 14, 2010 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.

"Based on the encouraging efficacy, safety and resistance data from the Phase 2a trial with PSI-7977 in combination with pegylated interferon and ribavirin, we initiated a study to explore shorter durations of interferon, including an interferon-free regimen in treatment naïve patients with HCV genotype 2 or 3," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer. "An important limitation to the current treatment of HCV patients is the use of interferon with its associated side effect profile. We believe that PSI-7977's high barrier to resistance and the lack of a significant effect of IL28B genotype in the Phase 2a trial provide us an opportunity with PSI-7977 to explore shorter durations of interferon, and potentially even removing it from the treatment regimen altogether."

About the TrialThe trial is anticipated to enroll approximately 40 patients infected with HCV genotype 2 or 3 who have not previously been treated. The primary endpoint of the trial will be the assessment of safety and tolerability of PSI-7977 400mg QD and RBV for 12 weeks, administered with or without pegylated interferon (Peg-IFN) in treatment naïve patients with HCV genotypes 2 or 3. The trial will be conducted in New Zealand. Patients will be randomized into one of 4 arms:

-- PSI-7977 400mg QD in combination with RBV for 12 weeks (no interferon);

-- PSI-7977 400mg QD in combination with RBV for 12 weeks,
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... DUBLIN , August 22, 2014 ... of Hospital TVs Today Lincor announced general ... Patient Engagement solution that delivers a range of education, ... sets.      (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , ... in defining point of care patient engagement to bedside ...
(Date:8/22/2014)... Aug. 22, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... William E. Saxelby , its President and Chief Executive ... Executive Officer and as a member of the Board ... will be replaced on an interim basis by ...
(Date:8/22/2014)... , Aug. 22, 2014  WaferGen Bio-systems, Inc. (NASDAQ: ... offering of units of common stock and warrants at ... of $20 million, prior to deducting underwriting discounts and ... shares and warrants are immediately separable and will be ... to begin trading on The NASDAQ Stock Market under ...
Breaking Medicine Technology:Lincor Unveils Next Generation TV-based Patient Engagement Solution 2Landauer, Inc. Announces Executive Management Change 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... MONMOUTH JUNCTION, N.J., March 29, 2011 Tris Pharma, ... anticipated re-launch of the MyKidz® Iron product ... has attracted a loyal following of pediatricians, pediatric nurses ... its product pipeline in a different direction, availability of ...
... NEW YORK, March 29, 2011 Reportlinker.com announces that a ... Top 150 Antibiotic Manufacturers (Global) ... Industry Report Plimsoll Publishing Ltd. Do ... in the industry? Which company has the highest ...
Cached Medicine Technology:Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements 2Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements 3Reportlinker Adds Top 150 Antibiotic Manufacturers (Global) 2Reportlinker Adds Top 150 Antibiotic Manufacturers (Global) 3Reportlinker Adds Top 150 Antibiotic Manufacturers (Global) 4
(Date:8/23/2014)... (PRWEB) August 23, 2014 The ... - Trends & Forecasts to 2018” defines and ... and forecasting of the global revenue and consumption. ... the global polycarbonate resin market with analysis of ... is segmented, and consumption and revenues are forecasted ...
(Date:8/23/2014)... York, New York (PRWEB) August 23, 2014 ... stemming from the 2012 GranuFlo and NaturaLyte dialysis ... multidistrict litigation underway in U.S. District Court, District ... an updated docket report issued by the U.S. ... 15th, at least 2,028 claims are pending in ...
(Date:8/23/2014)... August 23, 2014 Peripheral intervention surgeries ... remove plaques, etc, thereby addressing the root cause of ... of blood to the other part of the arteries ... blood. These procedures require the use of a catheter, ... and polymers), these catheters are inserted through a thin ...
(Date:8/23/2014)... According to the new research report, "Electronic ... - Regional Trends & Forecast to 2019," defines ... analysis and forecast of value individually. Along with ... by applications and geography are also discussed in ... and 26 figures spread through 234 pages and ...
(Date:8/23/2014)... PA (PRWEB) August 23, 2014 Having been ... and dental hygienist from Arlington, Texas, saw a need for ... and toothpaste. "That’s when I came up with the idea ... No-Brush provides an effective way for a user to clean ... need to carry multiple items. It also helps avoid plaque ...
Breaking Medicine News(10 mins):Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 4Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 3
... Medarex, Inc.,(Nasdaq: MEDX ) is scheduled to host ... Annual Meeting of the American Society of Clinical,Oncology (ASCO) ... at 8:00 a.m. Eastern Time / 7:00 a.m. Central ... be joined by Jedd D. Wolchok, M.D.,Ph.D., Director of ...
... Children Not Meeting Daily Physical,Activity Recommendations, INDIANAPOLIS, ... care homes are unlikely to be meeting physical ... released today,at the 55th Annual Meeting of the ... operated family child care homes, as the second,largest ...
... KV Expects Filings To Be Completed Within Automatic Form 10-K Extension ... ... ST. LOUIS, May 30 KV Pharmaceutical Company,(NYSE: KVa/KVb), a ... products and generic/non-branded prescription pharmaceuticals,announced today that it expects to complete ...
... new University of,Detroit Mercy School of Dentistry and Clinic ... from 9 a.m. to 1 p.m. on the new ... screenings for community,members, as well as oral health awareness ... of the School of Dentistry,s 75th,Anniversary., Over 211,000 ...
... 2008, New YorkThe number of uninsured young adults in the ... 13.3 million in 2005making the 19-to-29 age group one of ... insurance. According to a newly updated report from The Commonwealth ... attend college and 34 percent of college graduates will spend ...
... of Michigan,ranked among the nation,s top 30 hospitals ... America,s Best Children,s Hospitals. This publication,ranked each pediatric ... neonatal care, neurology and neurosurgery, respiratory,disorders, and general ... neurology and neurosurgery., U.S. News uses several ...
Cached Medicine News:Health News:Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO 2Health News:Preschoolers in Family Child Care Homes Need More Activity 2Health News:KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings 2Health News:KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings 3Health News:UDM School of Dentistry to Host Community Open House 2Health News:Young adults at risk: 13.7 million lack health insurance coverage 2Health News:Young adults at risk: 13.7 million lack health insurance coverage 3Health News:DMC Children's Hospital of Michigan Ranked Among America's Best 2
Fluoroperm 151 lens meets special needs of certain patients who need exceptional oxygen permeability for specific corneal condition or lifestyle requirements....
... Thinsite is designed using sophisticated lathing ... concepts. Thinsite lenses feature a center thickness ... ranges. While all plus powered Thinsite lenses ... over standard designs. The unique design eliminates ...
An easy-to-fit RGP daily wear lens with a unique bi-aspheric back surface design that provides excellent patient comfort and adaptation. Boston Envision contact lenses are an ideal alternative for vi...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
Medicine Products: